NEU-411
LRRK2-driven Parkinson's Disease
Key Facts
About Neuron23
Neuron23 is a private, clinical-stage biotech founded in 2018 that is pioneering a precision medicine paradigm for Parkinson's disease and other neurological conditions. Its core strategy integrates AI/ML-driven target discovery with the development of potentially best-in-class therapies, led by its lead asset NEU-411, a brain-penetrant LRRK2 inhibitor now in a global Phase 2 trial for genetically defined Parkinson's. The company is backed by significant venture capital, including a recent $96.5 million Series D, and is led by a team with deep expertise in neuroscience and drug development. Neuron23 aims to subset patient populations based on genetic drivers, similar to oncology, to deliver more effective treatments.
View full company profile